Prognostic significance of kappaB-Ras1 expression in gliomas

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1272-1279

  Lin, Hong ^a   Wang, YanGang ^a   Zhang, Xiang ^a   Liu, BoLin ^a   Zhang, Wei ^a   Cheng, JinXiang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

B Ras1; Glioma; NF kappa B; Survivin; Tumorigenesis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RAS PROTEIN; SURVIVIN; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; TUMOR MARKER;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADOLESCENT; AGED; BRAIN; BRAIN TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; BRAIN; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; I-KAPPA B PROTEINS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; RAS PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84866285042     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9835-x     Document Type: Article

References (31)

1. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009;472:323-42.
2. Pytel P, Lukas RV. Update on diagnostic practice: tumors of the nervous system. Arch Pathol Lab Med. 2009;133:1062-77.
3. Kanu OO, Mehta A, Di C, et al. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets. 2009;13: 701-18.
4. Robins HI, Lassman AB, Khuntia D. Therapeutic advances in malignant glioma: current status and future prospects. Neuroimag Clin N Am. 2009;19:647-56.
5. Sanai N, Berger MS. Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics. 2009;6:478-86.
6. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009;64:647-55.
7. Simpson L, Galanis E. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther. 2006;6:1593-607.
8. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596-606.
9. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood). 2008;233: 21-31.
10. Sebens S, Arlt A, Schäfer H. NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 2008;177:151-64.
11. Takamune Y, Ikebe T, Nagano O, Shinohara M. Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma. Biochem Biophys Res Commun. 2008;365:393-8.
12. Charalambous MP, Lightfoot T, Speirs V, Horgan K, Gooderham NJ. Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer. 2009;101:106-15.
13. Frasor J, Weaver A, Pradhan M, et al. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res. 2009;69:8918-25.
14. Kim JM, Voll RE, Ko C, Kim DS, Park KS, Kim SY. A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells. J Mol Biol. 2008;384:756-65.
15. Fenwick C, Na SY, Voll RE, et al. A subclass of Ras proteins that regulate the degradation of IkappaB. Science. 2000;287:869-73.
16. Huxford T, Ghosh G. Inhibition of transcription factor NF-kappaB activation by kappaB-Ras. Methods Enzymol. 2006;407: 527-34.
17. Chen F, Beezhold K, Castranova V. Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol. 2008;27:183-204.
18. Tsuboi Y, Kurimoto M, Nagai S, et al. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. J Neurosurg. 2009;110:594-604.
19. Erdamar S, Bagci P, Oz B, Dirican A. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON. 2006;11:213-6.
20. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006;12: 7261-70.
21. Salhia B, Tran NL, Symons M, Winkles JA, Rutka JT, Berens ME. Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn. 2006;6:613-26.
22. Steinbach JP, Weller M. Apoptosis in gliomas: molecular mechanisms and therapeutic implications. J Neurooncol. 2004;70: 245-54.
23. Gabellini C, Castellini L, Trisciuoglio D, Kracht M, Zupi G, Del Bufalo D. Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma. J Neurochem. 2008;107:871-82.
24. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NFjB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010;1799:775-87.
25. Annabi B, Laflamme C, Sina A, Lachambre MP, Béliveau R. A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133 + U87 glioblastoma cells. J Neuroinflammation. 2009;6:8.
26. Bhat KP, Pelloski CE, Zhang Y, et al. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Lett. 2008;582:3193-200.
27. Nozell S, Laver T, Moseley D, et al. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol. 2008;28:6632-45.
28. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 2007;22:1387-98.
29. Chen Y, Vallee S, Wu J, Vu D, Sondek J, Ghosh G. Inhibition of NF-kappaB activity by IkappaBbeta in association with kappaBRas. Mol Cell Biol. 2004;24:3048-56.
30. Zhen HN, Zhang X, Hu PZ, et al. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer. 2005;104:2775-83.
31. Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics. 2009;6:447-57.